Analysis of Bipolar Disorder Therapeutics market covering 30 + countries including analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
Demand for bipolar disorder therapeutic drugs is projected to increase at a CAGR of 3.1% from 2022 to 2026.
The global bipolar disorder therapeutics market will account for US$ 5.9 Bn in 2022, and is anticipated to reach a valuation of US$ 6.8 Bn by the end of 2026.
Bipolar Disorder Therapeutics Market Size (2022)
US$ 5.9 Bn
Projected Year Value (2026F)
US$ 6.8 Bn
Global Market Growth Rate (2022-2026)
United States Market Share (2022)
Key Companies Profiled
Consumption of bipolar disorder medications in China is expected to account for a revenue of approximately US$ 514 Mn by the end of 2026.
Increasing prevalence of bipolar disorders and rising awareness regarding mental health are major trends that will driving demand for bipolar disorder therapeutics over the years to come.
Don't Need a Global Report?
Save 40% on Country & Region specific reports
The world has witnessed an increase in focus on mental health over the past few years and this has been majorly driven by increasing stress levels among the population across the globe.
Increasing awareness for bipolar disorders from government initiatives has majorly increased the demand for bipolar disorder medications and is expected to be a prominent trend over the forecast period.
High-stress environments and increasing incidence of substance abuse are major bipolar disorder causes. Rising public awareness about bipolar disorders, rapid advancements in therapeutics development, and increasing caseload of bipolar disorders are other factors that will influence bipolar disorder therapeutics consumption through 2026.
However, the side effects associated with the use of bipolar disorder therapeutic medications are anticipated to hinder market potential throughout the forecast period. From 2022 to 2026, demand for bipolar disorder therapeutics is projected to rise at a steady CAGR of 3.1%.
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
“Increasing Prevalence of Mental Health Disorders across Geographies”
Over the past few years, the incidence of mental health disorders across the world has substantially increased and is expected to rise further over the forecast period.
Early onset of mental illnesses in teenagers and rising public awareness for mental health are major factors that influence bipolar disorder treatment market potential.
Demand for ADHD therapeutics, autism therapeutics, and seasonal affective disorder therapeutics is also expected to rise throughout the forecast period.
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
“Rising Awareness about Side Effects of Bipolar Disorder Therapeutic Medications Could Hinder Market Growth”
Side effects associated with the use of bipolar disorder therapeutic medications are anticipated to have a restraining effect on global market potential.
Rising awareness among the general population regarding ill effects associated with long-term use of bipolar disorder drugs and increasing patient preference for chemical-free bipolar disorder medication are factors that could slow down bipolar disorder therapeutics demand over the coming years.
“North America Accounts for Major Market Share”
The market for bipolar disorder therapeutics is projected to have a bright outlook in the region of North America owing to rising instances of bipolar disorders. This region is anticipated to hold a dominant market share over the forecast period.
Increasing awareness for bipolar disorders, the presence of advanced an healthcare system, rising incidence of bipolar disorders due to high-stress environments, and poor lifestyle habits are major factors that influence bipolar disorder therapeutics market growth through 2026. Increasing incidence of ADHD (Attention-deficit Hyperactivity Disorder) in this region will drive ADHD therapeutics demand.
Europe bipolar disorder therapeutics market is also anticipated to hold a significant market share owing to rising awareness for mental health and supportive government initiatives to boost the same. Consumption of bipolar disorder therapeutics equipment in Germany is anticipated to evolve at a CAGR of 2.6% throughout the forecast period.
Increasing prevalence of mental disorders in regions of South Asia and East Asia is expected to provide lucrative opportunities for bipolar disorder therapeutics device providers across the forecast period. The bipolar disorder therapeutics market in China is estimated to attain a net value of US$ 514 Mn by 2026.
India and China are projected to emerge as highly rewarding markets in these regions as awareness of bipolar disorders increases through 2026. Rising instances of autism in the aforementioned region are expected to propel the demand for autism therapeutics.
“High Incidence of Bipolar Disorders to Market Potential in U.S.”
The U.S. bipolar disorder therapeutics market currently accounts for 44.3% of the global bipolar disorder therapeutics industry landscape.
Increasing prevalence of bipolar disorders and rising awareness of mental health are two major trends that will drive bipolar disorder therapeutics market growth through 2026.
Currently, the bipolar disorder therapeutics market in the U.S. holds a net worth of US$ 2.6 Bn.
“Increasing Maniac Episodes & Prevalence of Depression to Drive Demand”
Mania and depression due to mental disorders is a common phenomenon and is often signified by mood swings and sudden mood changes. In order to control these and restore neurochemical balance, mood stabilizers are used and since episodes of depression and mania are on the rise these are anticipated to see high demand.
China, the United States, Canada, and Japan are projected to account for major demand for mood stabilizers through 2026.
The bipolar disorder therapeutics market saw a shift in trends as the sudden emergence of COVID-19 put the world in a state of shock. Lockdown restrictions were imposed across multiple nations as an effort to curb the spread of infections and this led to major changes in the world economy and affected various markets in different ways.
With a pandemic situation prevalent on a global scale and most of the world restricted from outdoor activity, a substantial change in mental health was observed under these challenging conditions. Although the demand for bipolar disorder medication was high in 2020, the market did not grow at its full potential owing to an increased focus on coronavirus infection control.
Allotment of major healthcare resources for pandemic led to a decreased focus on other health conditions and hence had a negative impact on the bipolar disorder therapeutics market growth. Consumption of bipolar disorder therapeutic drugs is expected to rise at a slow CAGR in the post-pandemic era owing to rising demand from the increasing caseload of mental health disorders.
Bipolar disorder treatment providers are investing in the research and development of novel therapeutics to expand their market presence across various regions. Bipolar disorder drug manufacturers are also pushing their offerings to get approvals from regulatory authorities.
- Premium Report Details -
- Let's Connect -
- Quick Contact -
- Get Started -
Get insights that lead to new growth opportunitiesBuy Now
Get A Special pricing for start-ups and universitiesEnquiry Before Buying
- Humble, Yet Honored -
- Research Methodology -
An Adaptive Approach to Modern-day Research NeedsGet Methodology
- Related Reports -
The global bipolar disorder therapeutics market stands at US$ 5.9 Bn in 2022.
By the end of 2026, the global market for bipolar disorder therapeutics is predicted to reach a valuation of US$ 6.8 Bn.
From 2022 to 2026, demand for bipolar disorder therapeutics is anticipated to progress at CAGR 3.1%.
Key bipolar disorder therapeutic drug manufacturers are Astellas Pharma Inc., Allergan plc., Johnson & Johnson, GlaxoSmithKline plc., AbbVie Inc., Pfizer Inc., Novartis International AG., Gedeon Richter Plc, Lundbeck A/S, Janssen Pharmaceutica N.V., and O
The U.S. bipolar disorder therapeutics market accounts for 44.3% of the global market share in 2022.
By 2026, the China bipolar disorder therapeutics market is anticipated to attain a net worth of US$ 514 Mn.
Need An Exclusive Report For Your Unique Requirement?